Abstract
Simple SummaryIn patients with prostate cancer, the use of new-generation hormonal therapy, added to androgen deprivation therapy, requires careful evaluation of cognitive function. The aim of this systematic review is to describe the evidence about cognitive function in randomized trials testing new-generation hormonal therapy (abiraterone, enzalutamide, apalutamide, darolutamide). For each trial, we assessed the availability of both investigator-assessed cognitive impairment and disorders and patient-reported evaluation of cognitive function. Out of 19 trials, the investigator-based evaluation of cognitive impairment was available in seven (36.8%), while patient-reported evaluation of cognitive function results was presented only in one trial (5.3%). This analysis shows that, despite cognitive deterioration could be relevant in patients with prostate cancer, clinical development of new-generation hormonal drugs has not included a systematic evaluation of cognitive function.In patients with prostate cancer, earlier use and longer duration of new-generation hormonal therapy (NGHT), added to androgen deprivation therapy, requires careful evaluation of cognitive function. The aim of this systematic review is to describe the evidence about cognitive function in all the randomized trials (RCTs) testing NGHT (abiraterone, enzalutamide, apalutamide, darolutamide). We assessed the availability of both investigator-assessed cognitive impairment and disorders and patient-reported evaluation of cognitive function. Nineteen RCTs (17,617 patients) were included. The investigator-based evaluation of cognitive impairment was available in seven RCTs (36.8%). In total, 19/19 RCTs (100%) included patient-reported outcomes (PROs) collection, but PRO tools adopted allowed evaluation of cognitive function in two RCTs (10.5%). Among them, PRO-based cognitive function results were presented only in one RCT (5.3%): in ENZAMET, mean changes from baseline were worse with enzalutamide than with placebo, but deterioration-free survival favored enzalutamide. Despite cognitive deterioration could be relevant, clinical development of NGHT has not included a systematic evaluation of cognitive function. Assessment by investigators is at risk of underreporting, and commonly used PROs do not allow proper cognitive function analysis. Furthermore, the methodology of analysis can jeopardize the interpretation of results. Although direct comparisons are scanty, there could be differences between different NGHTs.
Highlights
Patients with cancer may experience cognitive problems as a consequence of their treatment [1].Androgen deprivation therapy (ADT) is the mainstay of systemic treatment for patients with prostate cancer
The evidence about cognitive impairment in patients receiving ADT is variable, several studies have shown that ADT can produce a negative effect on cognitive functioning [4,5,6]
The aim of this review is to summarize the available patient-reported outcomes (PROs) results, in terms of cognitive function, in all randomized trials testing new-generation hormonal therapy (NGHT)
Summary
Patients with cancer may experience cognitive problems as a consequence of their treatment [1]. Androgen deprivation therapy (ADT) is the mainstay of systemic treatment for patients with prostate cancer. The results of studies trying to describe the association between ADT and both cognitive changes and other CNS effects in patients with prostate cancer are controversial [3]. The evidence about cognitive impairment in patients receiving ADT is variable, several studies have shown that ADT can produce a negative effect on cognitive functioning [4,5,6]. Patients receiving ADT could experience significant impairment on visuomotor tasks, while the differences found in the other cognitive domains (attention/working memory, executive function, language, verbal memory, visual memory, visuospatial ability) are less clear [4]. Impairment can already be evident 6–12 months after the beginning of treatment [6]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
